Mostra i principali dati dell'item
Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B
dc.creator | Papatheodoridi M., Hadziyannis E., Berby F., Zachou K., Testoni B., Rigopoulou E., Gatselis N.K., Lyberopoulou A., Vlachogiannakos I., Manolakopoulos S., Dalekos G.N., Zoulim F., Papatheodoridis G.V. | en |
dc.date.accessioned | 2023-01-31T09:44:49Z | |
dc.date.available | 2023-01-31T09:44:49Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1111/jvh.13211 | |
dc.identifier.issn | 13520504 | |
dc.identifier.uri | http://hdl.handle.net/11615/77856 | |
dc.description.abstract | Reliable predictors of outcomes after treatment discontinuation in HBeAg-negative chronic hepatitis B (CHB) patients have not been established. We investigated the role of hepatitis B surface antigen (HBsAg), interferon-inducible protein-10 (IP10) and hepatitis B core-related antigen (HBcrAg) serum levels as predictors of HBsAg loss, relapse and retreatment in noncirrhotic HBeAg-negative CHB patients who discontinued long-term antiviral therapy. All HBsAg-positive (n = 57) patients of the prospective DARING-B study were included and followed monthly for 3 months, every 2/3 months until month-12 and every 3/6 months thereafter. HBsAg, IP10 and HBcrAg levels were measured by enzyme immunoassays, and SCALE-B score was calculated. Twelve patients achieved HBsAg loss before retreatment with 18-month cumulative incidence of 25%. Independent predictors of HBsAg loss were baseline HBsAg and month-1 IP10 levels. Of 10 patients with baseline HBsAg ≤100 IU/mL, 70% cleared HBsAg and 10% required retreatment. Of 23 patients with baseline HBsAg >1000 IU/mL, 4% cleared HBsAg and 43% required retreatment. Of 24 patients with intermediate baseline HBsAg (100-1000 IU/mL), 17% cleared HBsAg and 21% required retreatment; in this subgroup, month-1 IP10 was significantly associated with HBsAg loss, which occurred in 30% and 7% of cases with IP10 >150 and ≤150 pg/mL, respectively. Baseline HBcrAg was undetectable in all patients who cleared HBsAg and was associated with retreatment. SCALE-B was associated with HBsAg loss but not with relapse or retreatment. In conclusion, HBsAg, IP10 and HBcrAg serum levels can be useful for the decisions and management of treatment discontinuation in noncirrhotic Caucasian patients with HBeAg-negative CHB. © 2019 John Wiley & Sons Ltd | en |
dc.language.iso | en | en |
dc.source | Journal of Viral Hepatitis | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074083065&doi=10.1111%2fjvh.13211&partnerID=40&md5=7efddd587f995116e23d551a87d1b583 | |
dc.subject | alanine aminotransferase | en |
dc.subject | albumin | en |
dc.subject | aspartate aminotransferase | en |
dc.subject | entecavir | en |
dc.subject | gamma interferon inducible protein 10 | en |
dc.subject | hemoglobin | en |
dc.subject | hepatitis B core antigen | en |
dc.subject | hepatitis B surface antigen | en |
dc.subject | tenofovir disoproxil | en |
dc.subject | virus DNA | en |
dc.subject | antivirus agent | en |
dc.subject | CXCL10 protein, human | en |
dc.subject | gamma interferon inducible protein 10 | en |
dc.subject | hepatitis B core antigen | en |
dc.subject | hepatitis B surface antigen | en |
dc.subject | hepatitis B(e) antigen | en |
dc.subject | adult | en |
dc.subject | alanine aminotransferase blood level | en |
dc.subject | albumin blood level | en |
dc.subject | Article | en |
dc.subject | aspartate aminotransferase blood level | en |
dc.subject | chronic hepatitis B | en |
dc.subject | clinical trial | en |
dc.subject | drug efficacy | en |
dc.subject | electrochemiluminescence | en |
dc.subject | female | en |
dc.subject | hemoglobin blood level | en |
dc.subject | high risk patient | en |
dc.subject | human | en |
dc.subject | incidence | en |
dc.subject | leukocyte count | en |
dc.subject | liver stiffness | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | microparticle enzyme immunoassay | en |
dc.subject | prediction | en |
dc.subject | priority journal | en |
dc.subject | prospective study | en |
dc.subject | protein blood level | en |
dc.subject | receiver operating characteristic | en |
dc.subject | relapse | en |
dc.subject | retrospective study | en |
dc.subject | sensitivity and specificity | en |
dc.subject | treatment duration | en |
dc.subject | treatment outcome | en |
dc.subject | treatment withdrawal | en |
dc.subject | aged | en |
dc.subject | blood | en |
dc.subject | chronic hepatitis B | en |
dc.subject | liver cirrhosis | en |
dc.subject | middle aged | en |
dc.subject | recurrent disease | en |
dc.subject | retreatment | en |
dc.subject | Aged | en |
dc.subject | Antiviral Agents | en |
dc.subject | Chemokine CXCL10 | en |
dc.subject | Female | en |
dc.subject | Hepatitis B Core Antigens | en |
dc.subject | Hepatitis B e Antigens | en |
dc.subject | Hepatitis B Surface Antigens | en |
dc.subject | Hepatitis B, Chronic | en |
dc.subject | Humans | en |
dc.subject | Liver Cirrhosis | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Prospective Studies | en |
dc.subject | Recurrence | en |
dc.subject | Retreatment | en |
dc.subject | Blackwell Publishing Ltd | en |
dc.title | Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |